Understanding the GAPA method
The Gene Activation Prediction Assay (GAPA) is the second technology platform in Biovator’s product line for predicting the allergenicity of chemical substances. Based on gene expression within a monocytic cell-line, the GAPA method is an in vitro assay where cultured human cells are exposed to Low Molecular Weight substances such as chemicals, drugs or cosmetics, after which the expression pattern in a given set of genes is analyzed using quantitative PCR. The assay was primarily developed for the prediction of skin sensitizers (i.e. Type IV allergens) but is also relevant for many low-molecular substances. The project is in late verification phase and a profile of genes has been selected for the coming pre-validation of the test in collaboration with BASF during 2010. The final version of the GAPA technology is expected to be ready to meet 2013 requirements for animal-free assays that can effectively test the allergenicity of chemical substances.
Commercial GAPA products will primarily be offered in the form of CRO services that can be routinely performed in typical molecular biology labs. Present results indicate that the test will be quicker and more cost-effective than the animal models used today.
Biovator has the complete competence to technically support a variety of user needs